Drug Trial Radar · NCT06308159
An Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia
Last checked: Nov 20, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
6
Planned (sponsor's estimate)
Start
May 11, 2024
Primary completion
Aug 1, 2027
Study completion Aug 1, 2027
Sponsor
- Lead sponsor
- Lantu BiopharmaIndustry
- Sponsor type
- Industry
- First posted
- Mar 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an interventional study to evaluate the safety and efficacy of autologous Hematopoietic Stem and Progenitor Cells (HSPCs) transduced with lentiviral vector encoding functional hemoglobin subunit beta (HBB) gene in patients with transfusion-dependent beta-thalassemia.
Conditions
- Beta-Thalassemia
Interventions
Vebeglogene autotemcelDrug
Autologous HSPCs transduced with self-inactivating lentiviral vector encoding functional HBB gene and resuspended in cryopreservative solution in the final immediate container for the intended medical use.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time and duration of the subject's hemoglobin (Hb)≥9.0 g/dL without receiving red blood cell infusionTime frame: From baseline to Month 24
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Kunming, Yunnan, China
Kunming Hope of Health Hospital
Kunming, Yunnan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.